Duloxetine Capsule, Delayed Release
Product Images NDC 70518-1765

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 70518-1765). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for Duloxetine 30 mg delayed-release capsules, with a quantity of 30 capsules. The label includes Dosage form as capsule and specifies the labeler as RemedyRepack Inc. The label shows NDC 70518-1765-00 and manufacturing information from Lupin Ltd, Goa, India. Directions reference a package insert and storage instructions are listed.*

FDA Label Image

C5b0f981 45c3 4e15 B712 984b4a4f6a57 01

Chemical structure of Duloxetine hydrochloride as shown in the product labeling, displaying the molecular arrangement including a thiophene ring, methylamine group, and naphthyl moiety.*

FDA Label Image

C5b0f981 45c3 4e15 B712 984b4a4f6a57 02

A Kaplan-Meier estimator curve showing the proportion of patients with relapse over a timeline of 0 to 200 days. The graph compares two treatments: placebo represented by a dashed line, and duloxetine represented by a solid line, illustrating lower relapse proportion in patients treated with duloxetine over time.*

FDA Label Image

C5b0f981 45c3 4e15 B712 984b4a4f6a57 03

Kaplan-Meier curve graph showing the proportion of patients with relapse over time (days) comparing Duloxetine to placebo treatment. The graph illustrates relapse rates from randomization up to approximately 250 days, with separate lines for Duloxetine and placebo groups.*

FDA Label Image

C5b0f981 45c3 4e15 B712 984b4a4f6a57 04

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares four groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), Duloxetine 20 mg once daily (QD), and Placebo, with higher improvement percentages associated with Duloxetine treatments compared to placebo.*

FDA Label Image

C5b0f981 45c3 4e15 B712 984b4a4f6a57 05

A line chart depicting percent improvement in pain from baseline on the x-axis versus percentage of patients improved on the y-axis. It compares three groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo. The chart shows the percentage of patients improving at varying levels of pain improvement.*

FDA Label Image

C5b0f981 45c3 4e15 B712 984b4a4f6a57 06

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo groups, illustrating patient improvement trends across varying levels of pain improvement.*

FDA Label Image

C5b0f981 45c3 4e15 B712 984b4a4f6a57 07

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares four groups: Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily, Duloxetine 60 mg once daily (likely a duplicate entry), and placebo. The graph shows trends in patient improvement across different pain reduction thresholds.*

FDA Label Image

C5b0f981 45c3 4e15 B712 984b4a4f6a57 08

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It includes two curves: one for placebo and one for Duloxetine 60/120 mg once daily. The vertical and horizontal axes are labeled, and vertical dashed lines mark specific improvement percentages.*

FDA Label Image

C5b0f981 45c3 4e15 B712 984b4a4f6a57 09

A line graph showing the percentage of patients improved over varying percentages of pain improvement from baseline (BOCF). Two lines compare placebo and Duloxetine 60 mg once daily, with the Duloxetine line consistently above the placebo line across the range from >0 to 100 percent improvement.*

FDA Label Image

C5b0f981 45c3 4e15 B712 984b4a4f6a57 10

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). Two curves compare placebo and duloxetine 60/120 mg once daily, with duloxetine consistently showing a higher percentage of patient improvement across different pain improvement percentages.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.